Clinical features, molecular diagnosis, and treatment outcome of infants with leukemia in Taiwan

Pediatric Blood and Cancer

Volumn 55, Issue 7, 2010, Pages 1264-1271

  Chen, Shih Hsiang ^a,b   Yang, Chao Ping ^a,b   Hung, Iou Jih ^a,b   Jaing, Tang Her ^a,b   Shih, Lee Yung ^a,b   Tsai, Ming Horng ^a,b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

Author keywords

Infant leukemia; MLL gene rearrangement; Prognosis

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; MIXED LINEAGE LEUKEMIA PROTEIN; PREDNISOLONE;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADVERSE OUTCOME; ARTICLE; BONE MARROW TRANSPLANTATION; CANCER CELL; CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER THERAPY; CHROMOSOME 11Q; CLINICAL FEATURE; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; CYTOGENETICS; EVENT FREE SURVIVAL; FEMALE; GENE REARRANGEMENT; GENETIC TRANSCRIPTION; HUMAN; IMMUNOPHENOTYPING; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; KARYOTYPE; LEUKOCYTE COUNT; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROGNOSIS; TAIWAN; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; GENE REARRANGEMENT; HUMANS; INFANT; LEUKEMIA; LEUKEMIA, MYELOID, ACUTE; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; LEUKOCYTE COUNT; MALE; MYELOID-LYMPHOID LEUKEMIA PROTEIN; MYELOPROLIFERATIVE DISORDERS; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TAIWAN; TREATMENT OUTCOME;

EID: 78049246451     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22731     Document Type: Article

References (49)

1. Biondi A, Cimino G, Pieters R, et al. Biological and therapeutic aspects of infant leukemia. Blood 2000; 96: 24-33.
2. Pui CH, Ribeiro RC, Campana D, et al. Prognostic factors in the acute lymphoid and myeloid leukemias of infants. Leukemia 1996; 10: 952-956.
3. Chessells JM, Harrison CJ, Kempski H, et al. Clinical features, cytogenetics and outcome in acute lymphoblastic and myeloid leukaemia of infancy: report from the MRC Childhood Leukaemia working party. Leukemia 2002; 16: 776-784.
4. Ishii E, Oda M, Kinugawa N, et al. Features and outcome of neonatal leukemia in Japan: experience of the Japan infant leukemia study group. Pediatr Blood Cancer 2006; 47: 268-272.
5. Silverman LB. Acute lymphoblastic leukemia in infancy. Pediatr Blood Cancer 2007; 49: 1070-1073.
6. Arico M, Biondi A, Pui CH. Juvenile myelomonocytic leukemia. Blood 1997; 90: 479-488.
7. Hilden JM, Dinndorf PA, Meerbaum SO, et al. Analysis of prognostic factors of acute lymphoblastic leukemia in infants: report on CCG 1953 from the Children's Oncology Group. Blood 2006; 108: 441-451.
8. Liang DC, Shih LY, Yang CP, et al. Multiplex RT-PCR assay for the detection of major fusion transcripts in Taiwanese children with B-lineage acute lymphoblastic leukemia. Med Pediatr Oncol 2002; 39: 12-17.
9. Liu HC, Chen SH, Chang KH, et al. Overall and event-free survivals for acute lymphoblastic leukemia in children at a single institution in Taiwan. Pediatr Hematol Oncol 2002; 19: 19-29.
10. Lin WY, Liu HC, Yeh TC, et al. Triple intrathecal therapy without cranial irradiation for central nervous system preventive therapy in childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2008; 50: 523-527.
11. Liang DC, Yang CP, Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 2009; 24: 397-405.
12. Steinherz PG, Gaynon P, Miller DR, et al. Improved disease-free survival of children with acute lymphoblastic leukemia at high risk for early relapse with the New York regimen-a new intensive therapy protocol: a report from the Childrens Cancer Study Group. J Clin Oncol 1986; 4: 744-752.
13. Reiter A, Schrappe M, Ludwig WD, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients. Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994; 84: 3122-3133.
14. Pui CH, Sandlund JT, Pei D, et al. Improved outcome for children with acute lymphoblastic leukemia: results of Total Therapy Study XIIIB at St Jude Children's Research Hospital. Blood 2004; 104: 2690-2696.
15. Liang DC, Shih LY, Hung IJ, et al. Clinical relevance of internal tandem duplication of the FLT3 gene in childhood acute myeloid leukemia. Cancer 2002; 94: 3292-3298.
16. Liang DC, Chan TT, Lin KH, et al. Improved treatment results for childhood acute myeloid leukemia in Taiwan. Leukemia 2006; 20: 136-141.
17. Shih LY, Huang CF, Wu JH, et al. Internal tandem duplication of FLT3 in relapsed acute myeloid leukemia: a comparative analysis of bone marrow samples from 108 adult patients at diagnosis and relapse. Blood 2002; 100: 2387-2392.
18. Thirman MJ, Gill HJ, Burnett RC, et al. Rearrangement of the MLL gene in acute lymphoblastic and acute myeloid leukemias with 11q23 chromosomal translocations. N Engl J Med 1993; 329: 909-914.
19. Rubnitz JE, Behm FG, Curcio-Brint AM, et al. Molecular analysis of t(11;19) breakpoints in childhood acute leukemias. Blood 1996; 87: 4804-4808.
20. Repp R, Borkhardt A, Haupt E, et al. Detection of four different 11q23 chromosomal abnormalities by multiplex-PCR and fluorescence-based automatic DNA-fragment analysis. Leukemia 1995; 9: 210-215.
21. Caligiuri MA, Strout MP, Schichman SA, et al. Partial tandem duplication of ALL1 as a recurrent molecular defect in acute myeloid leukemia with trisomy 11. Cancer Res 1996; 56: 1418-1425.
22. Fu JF, Liang DC, Yang CP, et al. Molecular analysis of t(X;11)(q24;q23) in an infant with AML-M4. Genes Chromosomes Cancer 2003; 38: 253-259.
23. Yang CP, Hung IJ, Jaing TH, et al. Cancer in infants: a review of 82 cases. Pediatr Hematol Oncol 2005; 22: 463-481.
24. Pui CH, Kane JR, Crist WM. Biology and treatment of infant leukemias. Leukemia 1995; 9: 762-769.
25. Greaves MF. Infant leukaemia biology, aetiology and treatment. Leukemia 1996; 10: 372-377.
26. Reaman GH, Sposto R, Sensel MG, et al. Treatment outcome and prognostic factors for infants with acute lymphoblastic leukemia treated on two consecutive trials of the Children's Cancer Group. J Clin Oncol 1999; 17: 445-455.
27. Rubnitz JE, Link MP, Shuster JJ, et al. Frequency and prognostic significance of HRX rearrangements in infant acute lymphoblastic leukemia: a Pediatric Oncology Group study. Blood 1994; 84: 570-573.
28. Cimino G, Rapanotti MC, Rivolta A, et al. Prognostic relevance of ALL-1 gene rearrangement in infant acute leukemias. Leukemia 1995; 9: 391-395.
29. Taki T, Ida K, Bessho F, et al. Frequency and clinical significance of the MLL gene rearrangements in infant acute leukemia. Leukemia 1996; 10: 1303-1307.
30. Sorensen PH, Chen CS, Smith FO, et al. Molecular rearrangements of the MLL gene are present in most cases of infant acute myeloid leukemia and are strongly correlated with monocytic or myelomonocytic phenotypes. J Clin Invest 1994; 93: 429-437.
31. Satake N, Maseki N, Nishiyama M, et al. Chromosome abnormalities and MLL rearrangements in acute myeloid leukemia of infants. Leukemia 1999; 13: 1013-1017.
32. Hilden JM, Smith FO, Frestedt JL, et al. MLL gene rearrangement, cytogenetic 11q23 abnormalities, and expression of the NG2 molecule in infant acute myeloid leukemia. Blood 1997; 89: 3801-3805.
33. Cimino G, Lo Coco F, Biondi A, et al. ALL-1 gene at chromosome 11q23 is consistently altered in acute leukemia of early infancy. Blood 1993; 82: 544-546.
34. Pieters R, den Boer ML, Durian M, et al. Relation between age, immunophenotype and in vitro drug resistance in 395 children with acute lymphoblastic leukemia-implications for treatment of infants. Leukemia 1998; 12: 1344-1348.
35. Dordelmann M, Reiter A, Borkhardt A, et al. Prednisone response is the strongest predictor of treatment outcome in infant acute lymphoblastic leukemia. Blood 1999; 94: 1209-1217.
36. Pui CH, Chessells JM, Camitta B, et al. Clinical heterogeneity in childhood acute lymphoblastic leukemia with 11q23 rearrangements. Leukemia 2003; 17: 700-706.
37. Ishii E, Kawasaki H, Isoyama K, et al. Recent advances in the treatment of infant acute myeloid leukemia. Leuk Lymphoma 2003; 44: 741-748.
38. Stong RC, Korsmeyer SJ, Parkin JL, et al. Human acute leukemia cell line with the t(4;11) chromosomal rearrangement exhibits B lineage and monocytic characteristics. Blood 1985; 65: 21-31.
39. Crist WM, Cleary ML, Grossi CE, et al. Acute leukemias associated with the 4;11 chromosome translocation have rearranged immunoglobulin heavy chain genes. Blood 1985; 66: 33-38.
40. Nagasaka M, Maeda S, Maeda H, et al. Four cases of t(4;11) acute leukemia and its myelomonocytic nature in infants. Blood 1983; 61: 1174-1181.
41. Gagnon GA, Childs CC, LeMaistre A, et al. Molecular heterogeneity in acute leukemia lineage switch. Blood 1989; 74: 2088-2095.
42. Stass S, Mirro J, Melvin S, et al. Lineage switch in acute leukemia. Blood 1984; 64: 701-706.
43. Stass S, Mirro J. Unexpected heterogeneity in acute leukemia: mixed lineages and lineage switch. Hum Pathol 1985; 16: 864-866.
44. Krawczuk-Rybak M, Zak J, Jaworowska B. A lineage switch from AML to ALL with persistent translocation t(4;11) in congenital leukemia. Med Pediatr Oncol 2003; 41: 95-96.
45. Jiang JG, Roman E, Nandula SV, et al. Congenital MLL-positive B-cell acute lymphoblastic leukemia (B-ALL) switched lineage at relapse to acute myelocytic leukemia (AML) with persistent t(4;11) and t(1;6) translocations and JH gene rearrangement. Leuk Lymphoma 2005; 46: 1223-1227.
46. Rubnitz JE, Lensing S, Zhou Y, et al. Death during induction therapy and first remission of acute leukemia in childhood: the St. Jude experience. Cancer 2004; 101: 1677-1684.
47. Creutzig U, Zimmermann M, Reinhardt D, et al. Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. J Clin Oncol 2004; 22: 4384-4393.
48. Pui CH, Jeha S. New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov 2007; 6: 149-165.
49. Liedtke M, Cleary ML. Therapeutic targeting of MLL. Blood 2009; 113: 6061-6068.